VFA
INSY

Virtus Fund Advisers’s Insys Therapeutics, Inc. INSY Stock Holding History

Virtus Fund Advisers’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,704
Closed -$27K – 2294
2014
Q2 		$27K Buy
+1,704
New +$27.5K ﹤0.01% 2274

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BTP
Bloom Tree Partners New York $215M AUM 17.45% 1-Year Est. Return

Virtus Fund Advisers's INSY Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Insys Therapeutics, Inc. (INSY) in Q3 2014, closing a stake of 1,704 shares — an estimated $27K sold.

Virtus Fund Advisers first reported a position in INSY in Q2 2014 and held it in 1 quarter. The position peaked at $27K in Q2 2014. 111 funds tracked by Wall St. Rank hold INSY as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Insys Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 1,704 Insys Therapeutics, Inc. shares in Q3 2014, an estimated $27K.
  • Virtus Fund Advisers first reported a position in Insys Therapeutics, Inc. in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Insys Therapeutics, Inc. position peaked at $27K in Q2 2014.
  • 111 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.